Dietary Supplements
Dietary Supplements
The world is experiencing a rapidly aging population since the twenty-first century. The UN projects the world population to reach 9.8 billion in the year 2050, with people over sixty-five reaching more than 1.5 billion, which make up nearly 16% of the population. Another study from WHO shows that only 5% of the population are healthy, 20% suffer from illnesses, and 75% are in various sub-optimal states.
Global aging and the universalization of the sub-optimal health status promote the accelerated market potential of health care products. Statistics show that the global health products industry market is expected to reach 438 billion USD by 2020; this market is expected to reach 600 billion USD by 2026, at a CAGR of 5.94% from 2021 to 2026.
The demand for health care products rapidly increases with the need for healthier well-being. Abiochem embraces this market opportunity to dive into the nutrition and health industry with the utilization of synthetic biology. Currently, Abiochem has made progress in the immunomodulation, anti-aging, and revitalization fields using our biosynthesis technology and comprehensive platforms.
NMN
NMN which has the full name β-nicotinamide mononucleotide is the precursor of nicotinamide adenine dinucleotide (NAD+) (coenzyme I) in human cells. Inside the human body, NMN plays an important role in energy and material metabolism. By applying advanced technology, Abiochem has successfully developed a novel in vitro biosynthetic route of NMN with fully independent intellectual property rights.
HMOs
As the 3rd largest solid component in human breast milk right after lactose and fat, Human Milk Oligosaccharides (HMOs) can promote the growth of probiotics and are widely used in infant/baby formulae as an additive. More than 200 different HMOs have been identified. Based on its innovation platforms such as “Intelligent Design”, “Enzyme Engineering”, “Genetic Engineering”, “Cell Foundry” and “Fermentation Engineering” and by applying advanced biosynthetic technology, Abiochem has successfully constructed the cell factory for the high-performance bio-manufacturing of HMOs series products, such as 2'-FL, with independent intellectual property rights.
